University of Edinburgh spin-out developing precision medicines for fibrosis across multiple organs. Forth combines single-cell and spatial genomics with computational models and machine learning to map disease-associated cells, identify antifibrotic targets and develop targeted therapies. Its platform draws on a large human liver-disease dataset and research led by scientific founder Neil Henderson. The company publicly describes three development assets but has not disclosed their specific molecular targets or clinical results. It operates from the Edinburgh and Cambridge research hubs with backing from Sofinnova Partners and Old College Capital.
Founded 2024
Team
Alex LeechChief Executive Officer and Board Director
